Decreased left ventricular stroke volume is associated with low-grade exercise tolerance in patients with chronic obstructive pulmonary disease

Sumito Inoue, Yoko Shibata, Hiroyuki Kishi, Joji Nitobe, Tadateru Iwayama, Yoshinori Yashiro, Takako Nemoto, Kento Sato, Masamichi Sato, Tomomi Kimura, Akira Igarashi, Yoshikane Tokairin, Isao Kubota

ABSTRACT

Background: Low-grade exercise tolerance is associated with a poor prognosis in patients with chronic obstructive pulmonary disease (COPD). The 6 min walk test (6MWT) is commonly used to evaluate exercise tolerance in patients with COPD. However, little is known regarding the relationship between cardiac function and exercise tolerance in patients with COPD. The aim of this study was to identify predictive factors in cardiac function for low-grade exercise tolerance in patients with stable COPD.

Methods: We recruited 57 patients with stable COPD (men 54, women 3) to perform the 6MWT. Patients with underlying orthopaedic disease or heart failure were excluded. Cardiac function was evaluated by echocardiography and contrast-enhanced cardiac CT. We also measured pulmonary function and the 6MWT distance.

Results: Forced expiratory volume in 1 s (FEV1) and per cent predicted FEV, along with left ventricular end diastolic volume and left ventricular cardiac output as measured by cardiac CT, were significantly related to the 6MWT distance. On multivariate analysis, left ventricular stroke volume was the factor most closely associated with a decreased walked distance in the 6MWT.

Conclusions: Decreased left ventricular stroke volume was associated with low-grade exercise tolerance in patients with stable COPD without heart failure.

KEY MESSAGES

▸ What is the most predictive clinical parameter for low-grade exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD)?
▸ We show that decreased left ventricular stroke volume obtained from cardiac CT scan was associated with low-grade exercise tolerance in patients with stable COPD.
▸ The data suggest that cardiac CT scanning may be beneficial for the evaluation of cardiac function and decreased left ventricular stroke volume was associated with low-grade exercise tolerance in patients with stable COPD.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality globally. In Japan, there is an 8% prevalence of airflow limitation in participants over 40 years old, and it is presumed that many patients with COPD remain undiagnosed.

Recently, COPD has come to be considered both a respiratory disease, and a systemic disease. The severity of COPD is usually categorised according to respiratory functions such as forced expiratory volume in 1 s (FEV1) and per cent predicted FEV (% FEV1). Although patients with COPD and compromised respiratory function have shown lower exercise tolerance, other factors including cardiac function, aerobic capacity, respiratory or skeletal muscle function, and dynamic hyperinflation have been previously associated with exercise tolerance.

Recently, a decreased exercise tolerance has been strongly associated with a poor prognosis, independent of pulmonary function. The BODE Index, determined by the body mass index (BMI), airway obstruction (as measured by FEV1), dyspnoea (as measured by the Modified Medical Research Council (mMRC) Dyspnea Scale), and exercise tolerance (as measured by the 6 min walk test (6MWT)), is one of the best predictors of mortality in patients with COPD. Owing to this, it is important to accurately assess exercise tolerance to predict the prognosis of patients with COPD. The 6MWT provides a practical and simple test to evaluate exercise tolerance in these patients.
Patients with COPD frequently experience exacerbations due to respiratory infection, respiratory failure and death.\textsuperscript{16} In addition to respiratory infections or respiratory failure, cardiovascular diseases have shown a significant association with COPD and are reported to be a major cause of death in patients with COPD.\textsuperscript{1} Based on these findings, we need to consider exercise tolerance and the presence of cardiovascular disease in the management of patients with COPD.

Echocardiography is commonly used to evaluate cardiac function. However, this method has serious limitations in the evaluation of some patients with COPD with overinflated lungs and persistent expansion of the thoracic wall. Ultrasonic waves are poorly transmitted through air, and do not conduct well in lung tissue. Overinflated lungs degrade the quality of cardiac imaging with echocardiography. However, recent technological developments in multidetector CT (MDCT) now enable the assessment of end-diastole and end-systole cardiac volumes. Therefore, an MDCT evaluation of cardiac function in patients with COPD may be superior to that obtained with echocardiography, because overinflated lungs do not limit the MDCT examination.

In this study, we evaluated cardiac function in patients with stable COPD using 64-slice MDCT, and analysed the correlations between cardiac functions and exercise tolerance. The aim of this study was to identify predictive factors in cardiac function for low-grade exercise tolerance in patients with stable COPD.

**MATERIALS AND METHODS**

**Participants**

We recruited 57 patients with stable COPD (54 men, 3 women) who were free of any exacerbations in the 3 months prior to this study. None of the 57 patients had any disability affecting their ability to perform the 6MWT, such as orthopaedic disease or heart failure. None of the patients with COPD had been diagnosed with heart failure by their physicians. All participants gave written informed consent. The diagnosis of COPD was based on spirometry demonstrating a postbronchodilator FEV\textsubscript{1}/forced vital capacity (FVC) ratio of <0.7.\textsuperscript{17} The reference values for respiratory function were based on guidelines from the Japanese Respiratory Society.\textsuperscript{18} Smoking habits were self-reported.

Patients with COPD underwent 6MWT following guidelines published by the American Thoracic Society (ATS).\textsuperscript{19} The patients walked on a flat, hard-surfaced corridor, and were encouraged every 60 s during the test. Patients were allowed to stop walking and rest during the test if they felt fatigue or dyspnoea; however, they were instructed to restart walking as soon as they were able to.\textsuperscript{19}

**Evaluation of cardiac function**

Cardiac function was evaluated by echocardiography and contrast-enhanced cardiac CT. Transthoracic echocardiography was performed (Hewlett-Packard/Philips Sonos 7500 ultrasound instrument, Philips Healthcare, Amsterdam, The Netherlands) and left ventricular (LV) and left atrial diameters were measured in the two-dimensional parasternal long-axis view. LV ejection fraction was calculated using the biplanar method of disks (modified Simpson rule).\textsuperscript{20} Cardiac MDCT was performed using a 64-slice MDCT scanner (Aquilion 64, Toshiba, Tokyo, Japan). A total of 51–100 mL of contrast media (Iopamidol, Bayer Co, Leverkusen, Germany) was injected at a flow rate of 3.0–4.6 mL/s, depending on the patient’s body weight. The region of interest was placed between the ascending aorta and descending aorta, and scanning was started when the CT density reached 250 Hounsfield units (HU) at the ascending aorta or 180 HU at the descending aorta. The area between the diaphragm and the tracheal bifurcation (collimation width 0.5 mm, rotation speed 0.4 s/rotation, tube voltage 120 kV and effective tube current 400–450 mA) was scanned. Cardiac images were evaluated during most of the motionless phase of the cardiac cycle, which was most frequently the mid-diastolic phase, with retrospective cardiac gating at 75% of the inter-beat (R-R) interval.\textsuperscript{21–23} This protocol was the same as that used in a previously reported study.\textsuperscript{23} An automatic algorithm in the analysis software (ZIO station, ZIO soft, Tokyo, Japan) was used\textsuperscript{20 22} to evaluate cardiac volumes and output. The patients’ profiles, respiratory function and cardiac parameters measured by MDCT or echocardiography are summarised in table 1.

**Statistical analyses**

All data are expressed as means±SD. The relationships between continuous variables were evaluated using Spearman’s rank correlations. Univariate and multivariate analyses were used to identify risk factors for low-grade exercise tolerance with the 6MW. We used a distance of 350 m in the 6MW as the cut-off value in the univariate and multivariate analysis, because this distance was used as the cut-off value in previous studies to determine low-grade exercise tolerance in patients with COPD.\textsuperscript{11 14 15} We used the receiver operating characteristic (ROC) curve to determine the cut-off value for LV stroke volume (LVSV), for detecting the risk for <350 m in the 6MW. All statistical analyses were performed using JMP V11.0.0 software (SAS Institute, Cary, North Carolina, USA). A p<0.05 was defined as statistically significant.

**RESULTS**

We compared the cardiac parameters obtained from echocardiography and MDCT. In 3/57 patients, we were unable to measure cardiac parameters with echocardiography because of their overinflated lungs. There was a significant correlation between the LV diastolic diameter, obtained from echocardiography, and the LV end diastolic volume (LVEDV), obtained from MDCT (R=0.339,
There was also a significant correlation in the ejection fraction obtained with both methods (R=0.549, p<0.001; figure 1B). We also analysed the correlation between clinical background and data and the 6MWT distance in patients with COPD (table 2).

There was no correlation between age and BMI with the 6MWT distance. Per cent predicted FVC, %FEV₁, FEV₁/FVC and inspiratory capacity (IC) showed a significantly positive correlation with the 6MWT distance. In addition, cardiac parameters derived from MDCT imaging, including LVEDV, LVEDV index (LVEDV/body surface area), LVSV, LV cardiac output (LVCO) and LV cardiac index (LVCO/body surface area) demonstrated a significantly positive correlation with the 6MWT distance. In contrast with the cardiac parameters measured by MDCT, there were no significant correlations between cardiac parameters measured by echocardiography and the 6MWT distance.

Since a <350 m 6MWT distance was used in a previous study as the cut-off value for low-grade exercise tolerance in patients with COPD,¹⁵ we used this cut-off value in the univariate and multivariate analysis (table 3). In this study, 11 patients did not reach a distance of 350 m in the 6MWT.

In the univariate analysis, a decreased %FEV₁, IC and LVSV were significant risk factors for a shorter 6MWT distance.

---

**Table 1** Profiles of patients (n=57)

| Parameter                        | Mean ± SD |
|----------------------------------|-----------|
| Gender: male (%)                 | 54 (94.7%)|
| Age (years)                      | 71.5±8.0  |
| BMI (kg/m²)                      | 21.5±3.2  |
| Brinkman index                   | 1197±602  |
| mMRC scale (0/1/2/3/4)           | 14/30/9/2/2|
| GOLD classification: I/II/III/IV  | 10/16/25/6|
| Distance in 6MWT (m)             | 418.2±103.9|
| Respiratory function             |           |
| FVC (L)                          | 2.82±0.79 |
| %FVC (%)                         | 98.6±27.2 |
| FEV₁ (L)                         | 1.33±0.57 |
| FEV₁/FVC (%)                     | 46.2±10.2 |
| FEV₁/FVC*p (%)                   | 51.9±20.9 |
| IC (L)                           | 1.99±0.56 |
| Cardiac parameters measured by MDCT |           |
| LVEF (%)                         | 53.5±10.9 |
| LVEDV (mL)                       | 96.5±34.3 |
| LVEDVI (mL/m²)                   | 61.6±22.7 |
| LVESV (mL)                       | 46.3±24.1 |
| LVESVI (mL/m²)                   | 29.5±16.4 |
| LVSV (mL)                        | 50.4±16.6 |
| LVCO (L/min)                     | 3.6±1.2   |
| LVCI (L/min/m²)                  | 2.3±0.8   |
| RVEF (%)                         | 34.4±12.5 |
| RVEDV (mL)                       | 121.5±38.4|
| RVEDVI (mL/m²)                   | 77.2±23.1 |
| RVESV (mL)                       | 80.2±32.2 |
| RVESVI (mL/m²)                   | 51.0±19.7 |
| RVSV (mL)                        | 41.2±18.7 |
| RVCO (L/min)                     | 3.0±1.2   |
| RVCI (L/min/m²)                  | 1.9±0.8   |
| Cardiac parameters measured by echocardiography |           |
| LVDd (mm)                        | 45.0±7.4  |
| LVDs (mm)                        | 28.1±5.8  |
| LVEF (%)                         | 68.5±9.7  |
| TR-PG (mm Hg)                    | 15.5±13.8 |

6MWT, 6 min walk test; BMI, body mass index; FEV₁, forced expiratory volume in 1 s; %FVC, per cent predicted FVC; FVC, forced vital capacity; IC, inspiratory capacity; LVCI, left ventricular cardiac index; LVCO, left ventricular cardiac output; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEDV, left ventricular end diastolic volume; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVESVI, left ventricular end systolic volume index; LVSV, left ventricular stroke volume; MDCT, multidetector CT; mMRC, modified British Medical Research Council; RVCI, right ventricular cardiac index; RVCO, right ventricular cardiac output; RVDD, right ventricular diastolic diameter; RVDDI, right ventricular end diastolic volume index; RVESV, right ventricular end systolic volume; RVESVI, right ventricular end systolic volume index; RVSV, right ventricular stroke volume; TR-PG, tricuspid regurgitation-pressure gradient.

FEV₁/FVC and inspiratory capacity (IC) showed a significantly positive correlation with the 6MWT distance. In addition, cardiac parameters derived from MDCT imaging, including LVEDV, LVEDV index (LVEDV/body surface area), LVSV, LV cardiac output (LVCO) and LV cardiac index (LVCO/body surface area) demonstrated a significantly positive correlation with the 6MWT distance. In contrast with the cardiac parameters measured by MDCT, there were no significant correlations between cardiac parameters measured by echocardiography and the 6MWT distance.

Since a <350 m 6MWT distance was used in a previous study as the cut-off value for low-grade exercise tolerance in patients with COPD,¹⁵ we used this cut-off value in the univariate and multivariate analysis (table 3). In this study, 11 patients did not reach a distance of 350 m in the 6MWT.

In the univariate analysis, a decreased %FEV₁, IC and LVSV were significant risk factors for a shorter 6MWT distance.
The results of the multivariate analyses are shown in table 4. Parameters obtained from cardiac CT were strongly associated with each other (data not shown). LVSV was thought to be the best predictor of low-grade exercise capacity because it showed the lowest p value among all cardiac parameters (table 2). Therefore, LVSV was applied in the multivariate analyses. Furthermore, there was a strong association between low-grade exercise capacity and %FEV1 and IC (R=0.658, p<0.0001), and these were separately included in the multivariate analyses (table 4, models A and B).

LVSV was a significant predictive factor for low-grade exercise tolerance, independent of age, BMI and pulmonary functions including %FEV1 (model A) and IC (model B). We used a ROC curve analysis to determine the LVSV cut-off value for discriminating between patients with COPD who could or could not walk 350 m in the 6MWT. The area under the curve was 0.844, and the cut-off value was 42.2 mL, with a sensitivity of 0.8261 and a specificity of 0.8182 (p=0.004; figure 2).

**DISCUSSION**

In this study, we showed that a decreased LVSV is associated with a reduced exercise tolerance in patients with stable COPD. In these patients, the 6MWT distance was significantly correlated with pulmonary functions indicating the degree of airflow limitation (%FEV1) and air trapping (IC). The 6MWT distance was also significantly correlated with cardiac function, such as LVSV, measured by cardiac CT scanning. However, there was no correlation between exercise tolerance and age, BMI or cardiac parameters measured by echocardiography. In the univariate and multivariate analyses, decreased LVSV was the most significant predictive factor for low-grade exercise tolerance.

Cardiovascular diseases are reported to be a major cause of death in patients with COPD: ~27% of these patients die of cardiovascular diseases including atherosclerosis and heart failure.1 Echocardiography is a simple, non-invasive and commonly used method for the evaluation of cardiac function. However, echocardiography is sometimes difficult in patients with COPD.

---

**Table 2** Correlation between distance in 6MWT and parameters

| R   | p Value |
|-----|---------|
| Age | 0.241   | 0.0702 |
| BMI | 0.221   | 0.0988 |

**Respiratory function**

| %FVC | 0.341 | 0.0094 |
| %FEV1 | 0.366 | 0.0051 |
| FEV1/FVC | 0.329 | 0.0124 |
| IC | 0.453 | 0.0004 |

**Cardiac parameters measured by MDCT**

| LVSV | 0.458 | 0.0003 |
| LVCO | 0.390 | 0.0027 |
| LVCI | 0.333 | 0.0114 |
| RVEF | 0.226 | 0.0910 |
| RVEDV | 0.193 | 0.1499 |
| RVEDV | 0.149 | 0.2689 |
| RVEF | 0.071 | 0.6001 |
| RVESVI | 0.026 | 0.7959 |
| RVSV | 0.275 | 0.0385 |
| RVCO | 0.195 | 0.1455 |
| RVCI | 0.167 | 0.2138 |

**Cardiac parameters measured by echocardiography**

| LVDD | 0.055 | 0.6891 |
| LVDs | 0.026 | 0.8529 |
| LVIF | 0.122 | 0.3715 |
| TR-PG | 0.144 | 0.3001 |

Clinical data for each parameter are described in table 1. 6MWT, 6 min walk test; BMI, body mass index; %FEV1, per cent predicted FEV1; FEV1, forced expiratory volume in 1 s; %FVC, per cent predicted FVC; FVC, forced vital capacity; IC, inspiratory capacity; LVCI, left ventricular cardiac index; LVCO, left ventricular cardiac output; LVDD, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEDV, left ventricular end diastolic volume; LVEDVI, left ventricular end diastolic volume index; LVIF, left ventricular ejection fraction; LVSV, left ventricular stroke volume; LVESVI, left ventricular end systolic volume index; LVSV, left ventricular stroke volume; MDCT, multidetector CT; RVCI, right ventricular cardiac index; RVCO, right ventricular cardiac output; RVDD, right ventricular diastolic diameter; RVDDVI, right ventricular end diastolic volume index; RVIF, right ventricular ejection fraction; RVSV, right ventricular stroke volume; RVCO, right ventricular stroke volume; TR-PG, tricuspid regurgitation-pressure gradient.

**Table 3** Univariate analysis to detect the risk of shorter distance of 6MWT

| OR   | 95% CI       | p Value |
|------|--------------|---------|
| Age, per 1SD increase | 1.76 | 0.86 to 4.03 | 0.1237 |
| BMI, per 1SD increase | 0.70 | 0.33 to 1.38 | 0.3156 |
| %FEV1, per 1SD increase | 0.31 | 0.10 to 0.75 | 0.0064 |
| IC, per 1SD increase | 0.46 | 0.20 to 0.94 | 0.0317 |
| LVSV, per 1SD increase | 0.15 | 0.03 to 0.45 | 0.0002 |

6MWT, 6 min walk test; BMI, body mass index; %FEV1, per cent predicted FEV1; FEV1, forced expiratory volume in 1 s; IC, inspiratory capacity; LVSV, left ventricular stroke volume.
In conclusion, decreased LVSV was associated with low-grade exercise tolerance in patients with COPD not diagnosed with heart failure. Cardiac CT scanning may be beneficial for the evaluation of cardiac function and atherosclerosis of the coronary arteries in patients with COPD. Further investigation is needed to determine the relationship between disease progression and prognosis in patients with COPD and the cardiac parameters obtained from cardiac CT scanning.

**Contributors** SI planned the study and wrote the manuscript. YS advised the plan of the study and proofread the manuscript. HK and TN performed entry of the data. JN and YY analysed data of CT scan. TI performed echocardiography. KS performed statistical analysis. MS and YT performed pulmonary function test. TK and AI performed 6MWT. IK conducted the study.
REFERENCES

1. Rabe KF. Treating COPD—the TORCH trial, p values, and the Doda. N Engl J Med 2007;356:851–4.

2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613–20.

3. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Takahata study. Intern Med 2010;49:1489–99.

4. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1179–84.

5. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.

6. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. Respir Res 2004;5:179.

7. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:457.

8. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14–20.

9. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;23:28–33.

10. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med 2010;104:849–57.

11. Cuttica MJ, Shah SJ, Rosenberg SR. Right heart structural changes are independently associated with exercise capacity in non-severe COPD. PLoS ONE 2011;6:e29069.

12. Tzani P, Piepoli MF, Longo F, et al. Resting lung function in the assessment of the exercise capacity in patients with chronic heart failure. Am J Med Sci 2010;339:210–15.

13. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–12.

14. Hernandez NA, Wouters EF, Meijer K, et al. Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J 2011;38:261–7.

15. Inoue S, Nakamura H, Otake K, et al. Impaired pulmonary inflammatory responses are a prominent feature of streptococcal pneumonia in mice with experimental emphysema. Am J Respir Crit Care Med 2003;167:764–70.

16. COPD Diagnosis and Management At-A-Glance Desk Reference. http://www.goldcopd.org/uploads/users/files/GOLD_AgA_Glance_2013_Feb20.pdf

17. The Committee of Pulmonary Physiology JRS. Guidelines for pulmonary function tests: spirometry, flow-volume curve, diffusion capacity of the lung. Tokyo: Japanese Respiratory Society, 2004. http://www.jrs.or.jp/jp/quicklink/glm/guideline/nopass_pdf/spirogram.pdf

18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–17.

19. Watanabe T, Iwayama T, Nitobe J, et al. Predictors of left atrial coagulation activity among paroxysmal atrial fibrillation patients. Circ J 2015;79:61–9.

20. Harada K, Amano T, Uetani T, et al. Association of inflammatory markers with the morphology and extent of coronary plaque as evaluated by 64-slice multidetector computed tomography in patients with stable coronary artery disease. Int J Cardiovasc Imaging 2013;29:1149–58.

21. Iwayama T, Nitobe J, Watanabe T, et al. Role of epicardial adipose tissue in coronary artery disease in non-obese patients. J Cardiol 2012;59:344–9.

22. Inoue S, Shibata Y, Kishi H, et al. Low arterial blood oxygenation is associated with calcification of the coronary arteries in patients with chronic obstructive pulmonary disease. Respir Investig 2015;53:116–16.

23. Matsuyama W, Ohkubo R, Michizono K, et al. Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients. Eur Respir J 2001;17:1128–31.

24. Enfield K, Gammon S, Floyd J, et al. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2010;30:195–202.

25. Barr RG, Bluemke DA, Ahmed FS, et al. Relationship between pulmonary function tests: spirometry, flow-volume curve, diffusion capacity of the lung. Tokyo: Japanese Respiratory Society, 2004. http://www.jrs.or.jp/jp/quicklink/glm/guideline/nopass_pdf/spirogram.pdf

26. Yashiro Y, Arimoto T, Hashimoto N, et al. Determinants of poor exercise capacity in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2010;30:195–202.

27. McManus W, Ohkubo R, Michizono K, et al. Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients. Eur Respir J 2001;17:1128–31.

28. Enfield K, Gammon S, Floyd J, et al. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2010;30:195–202.

29. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217–27.

30. Greupner J, Zimmermann E, Grohmann A, et al. Head-to-head comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard. J Am Coll Cardiol 2012;59:1897–907.

31. Lopes AJ, Mafort TT. Correlations between small airway function, ventilation distribution, and functional exercise capacity in COPD patients. Lung 2014;192:653–9.